PR Newswire
ROCKVILLE, Md., March 7, 2017
ROCKVILLE, Md., March 7, 2017 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a late-stage
clinical company developing therapeutics that preserve the microbiome to protect and restore the health of patients, announced
today that Jeffrey Riley, President & Chief Executive Officer, is scheduled to present at the
29th Annual ROTH Conference being held March 12-15 at the Ritz-Carlton, Laguna Niguel in Dana Point, CA. Mr. Riley is scheduled to present on
Wednesday, March 15, 2016 at 8:00 a.m. (Pacific Time)/11:00 a.m. (Eastern Time).
A live webcast of Synthetic Biologics' presentation may be accessed by logging onto the web at http://wsw.com/webcast/roth31/syn. After the presentation,
a replay will be archived and accessible for 60 days at the same website.
About Synthetic Biologics, Inc.
Synthetic Biologics, Inc. (NYSE MKT: SYN) is a late-stage clinical company developing therapeutics designed to preserve the
microbiome to protect and restore the health of patients. The Company's lead candidates poised for Phase 3 development are: (1)
SYN-010 which is intended to reduce the impact of methane producing organisms in the gut microbiome to treat an underlying cause
of irritable bowel syndrome with constipation (IBS-C), and (2) SYN-004 (ribaxamase) which is designed to protect the gut
microbiome from the effects of certain commonly used intravenous (IV) beta-lactam antibiotics for the prevention of C.
difficile infection (CDI), antibiotic-associated diarrhea (AAD) and the emergence of antimicrobial resistance (AMR). The
Company is also developing preclinical stage monoclonal antibody therapies for the prevention and treatment of pertussis and
novel discovery stage biotherapeutics for the treatment of phenylketonuria (PKU). For more information, please visit Synthetic
Biologics' website at www.syntheticbiologics.com.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/synthetic-biologics-to-present-at-the-29th-annual-roth-conference-300418762.html
SOURCE Synthetic Biologics, Inc.
